Last reviewed 2026-05-26 · How we verify

CLM2 topical gel

Glia, LLC · Phase 2 active Small molecule Under review

CLM2 topical gel is a Small molecule drug developed by Glia, LLC. It is currently in Phase 2 development for Pain relief for musculoskeletal conditions.

CLM2 topical gel is a treatment for pain relief by targeting the underlying cause of pain.

CLM2 topical gel is a treatment being studied for conditions related to contact lens wear, including Contact Lens Discomfort, Contact Lens-induced Corneal Disorder, Contact Lens Acute Red Eye, and Contact Lens-induced Corneal Fluorescein Staining. The exact mechanism of CLM2 topical gel is currently unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLM2 topical gel
Sponsor	Glia, LLC
Modality	Small molecule
Therapeutic area	Pain Management
Phase	Phase 2

Mechanism of action

CLM2 topical gel works by interacting with the nervous system to reduce pain perception. This is achieved through a specific mechanism that has not been fully disclosed by the manufacturer. Further research is needed to fully understand the mechanism of action.

Approved indications

Pain relief for musculoskeletal conditions

Common side effects

Skin irritation

Key clinical trials

Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CLM2 topical gel CI brief — competitive landscape report
CLM2 topical gel updates RSS · CI watch RSS
Glia, LLC portfolio CI

Frequently asked questions about CLM2 topical gel

What is CLM2 topical gel?

CLM2 topical gel is a Small molecule drug developed by Glia, LLC, indicated for Pain relief for musculoskeletal conditions.

How does CLM2 topical gel work?

CLM2 topical gel is a treatment for pain relief by targeting the underlying cause of pain.

What is CLM2 topical gel used for?

CLM2 topical gel is indicated for Pain relief for musculoskeletal conditions.

Who makes CLM2 topical gel?

CLM2 topical gel is developed by Glia, LLC (see full Glia, LLC pipeline at /company/glia-llc).

What development phase is CLM2 topical gel in?

CLM2 topical gel is in Phase 2.

What are the side effects of CLM2 topical gel?

Common side effects of CLM2 topical gel include Skin irritation.

Manufacturer: Glia, LLC — full pipeline
Therapeutic area: All drugs in Pain Management
Indication: Drugs for Pain relief for musculoskeletal conditions

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing